- NSE
Sun Pharmaceutical Industries Limited
Healthcare SUNPHARMA
1703.30INR
75.40
(
4.63%)
Last update at
Day Range
52 Week Range
Fundamentals
- Previous Close 1627.90
- Market Cap 4224508.76M
- Volume4,255,742
- P/E Ratio 40.32
- EBITDA 156681.99M
- Revenue TTM 549640.11M
- Revenue Per Share TTM 229.07
- Gross Profit TTM 429776.99M
- Diluted EPS TTM 43.67
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Past Performance
| Status | Stocks | Entry Price | Entry Date | Exit Date | Duration | Duration Type | Sector | *Return(%) |
|---|---|---|---|---|---|---|---|---|
| CLOSED | SUNPHARMA | ₹ 1690.25 | 17/03/25 | 25/03/25 | 8 Days | Short Term | Healthcare | 5.90% |
| CLOSED | SUNPHARMA | ₹ 1628.75 | 10/03/25 | 10/03/25 | Same Day | Short Term | Healthcare | -1.15% |
Financials
Income Statement
Balance Sheet
Change in Cash
| Breakdown | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Income before tax | 137367.80M | 110494.80M | 94084.30M | 44813.20M | 27993.70M |
| Net income | 109290.40M | 95763.80M | 84735.80M | 32727.30M | 29038.20M |
| Total Revenue | 525784.40M | 484968.50M | 432788.70M | 384264.20M | 331391.80M |
| Gross Profit | 410199.90M | 370546.70M | 326167.10M | 267187.70M | 232537.60M |
| Breakdown | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
| Total assets | 921005.80M | 854628.80M | 807435.90M | 697998.70M | 676667.30M |
| Intangible assets | 90205.40M | 86662.60M | 93268.40M | 60282.00M | 56606.60M |
| Other current assets | 43473.10M | 27879.20M | 19402.50M | 540.90M | 508.20M |
| Deferred long term liab | - | - | - | - | - |
| Non current assets other | - | - | - | - | - |
| Breakdown | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
| Change in Cash | 9831.20M | 46619.20M | 1154.80M | -17647.80M | 5964.20M |
| Operating Cash | 140720.90M | 121349.80M | 49593.30M | 89845.40M | 61703.70M |
| Free Cash Flow | 119435.10M | 99331.70M | 28737.50M | 74895.00M | 50002.40M |
Peer Comparison
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
| Company | Change | Price | Market Cap (M) | P/E Ratio |
|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited |
75.40 4.63% | 1703.30 | 4224508.76 | 40.32 |
| DIVISLAB Divi's Laboratories Limited |
336.50 5.65% | 6289.00 | 1752225.28 | 70.47 |
| TORNTPHARM Torrent Pharmaceuticals Limited |
39.90 1.00% | 4027.10 | 1362716.66 | 63.48 |
| CIPLA Cipla Limited |
16.40 1.25% | 1328.00 | 1183505.97 | 21.74 |
| DRREDDY Dr. Reddy's Laboratories Limited |
53.70 4.54% | 1236.20 | 1004813.29 | 17.16 |
Profile
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including neuropsychiatry, cardiology, diabetes, gastroenterology, pain/analgesics, gynecology, ophthalmology, urology, dermatology, respiratory, anti-infectives, oncology, psychiatry, neurology, orthopaedic, nephrology, urology, dermatology, respiratory, dental, and nutritionals. It also provides generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; speciality medications; antiretrovirals medications; and over-the-counter products, such as vitamins, analgesics, digestives, and lifestyle. In addition, the company offers APIs for anti-cancers, peptides, steroids, sex hormones, immunosuppressant drugs, and controlled substances. It exports its products to approximately 90 countries across Asia, North America, Europe, Africa, South America, and Australia. Sun Pharmaceutical Industries Limited was founded in 1983 and is headquartered in Mumbai, India.
Sun Pharmaceutical Industries Limited
Sun House, Mumbai, India, 400063
- 91 22 4324 4324
- https://sunpharma.com
- Employees : 43,000
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Dilip Shantilal Shanghvi | MD & Exec. Director | 1955 |
| Mr. Kalyanasundaram Subramanian | Director of Corp. Devel. & Whole-time Director | 1954 |
| Mr. Sailesh Trambaklal Desai | Whole Time Director | 1954 |
| Mr. C. S. Muralidharan | Chief Financial Officer | 1963 |
| Mr. Davinder Singh | Exec. Vice-Pres of Global Operations | NA |
| Mr. Anil M. Rao | Sr. VP & Chief Information Officer | 1969 |
| Mr. Nimish Desai | Head of Investor Relations | NA |
| Mr. Anoop Deshpande | Company Sec. & Compliance Officer | NA |
| Dr. Sapna Purohit | Sr. VP & Head of HR | NA |
| Mr. Kirti Wardhaman Ganorkar | Chief Exec. Officer of India Bus. | 1967 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data ("EODHD") on an 'as is' basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.